

Press Release

08 • 08 • 2006



GENIZON
BioSciences

Genizon BioSciences Inc.
880 McCaffrey St.
St. Laurent, Quebec H4T 2C7
Tel : (514) 270-3991
Fax : (514) 270-5291
1-888-244-0388
www.genizon.com

GENIZON BIOSCIENCES LICENSES CROHN'S DISEASE GENEMAP TO GENENTECH

Results of whole genome association study to be used to support development of new therapeutics and diagnostics

Montreal, Quebec – August 8, 2006 –Genizon BioSciences today announced a license and collaboration agreement with Genentech, Inc. (NYSE:DNA) of South San Francisco, Calif. Genizon grants Genentech an exclusive license to Genizon's GeneMap of disease-associated genes generated from a whole genome association study of Crohn's disease patients from the Quebec Founder Population.

Under the terms of the agreement, Genizon will receive an upfront payment, research funding and milestone payments for each therapeutic product that may emerge from the collaboration. Financial terms were not disclosed.

"We are very pleased to enter into this collaboration with Genentech, a biotechnology pioneer with the scientific expertise to support the success of our Crohn's program," said John Hooper, Ph.D., President and CEO of Genizon. "We will work with Genentech to target key elements in the GeneMap to discover and develop potential new therapeutic products for Crohn's disease. We expect to also identify diagnostics that will aid patient selection and assist in identifying patient response factors."

Genizon's GeneMap for Crohn's disease was constructed from a whole genome association study of 500 families from the Quebec Founder Population, which, because of its genetic homogeneity is believed to be among the best populations worldwide for genetic research. Dr. Stefan Schreiber and the University Hospital of Schleswig-Holstein collaborated in this research.

About Genizon BioSciences

Genizon BioSciences Inc., founded in 1999, is the only source for GeneMaps—comprehensive maps of genes, biochemical pathways and drug targets that are unequivocally involved in causing human disease—accelerating the development of safer, more effective medicines. Genizon's proprietary, automated gene discovery platform using whole-genome association studies involving thousands of members of the Quebec Founder Population provides unprecedented understanding of the genetic origins and mechanisms of common diseases, resulting in the best possible drug targets. The company's GeneMaps provide pharmaceutical partners with intellectual property that creates opportunities for leadership in many therapeutic areas by bringing to market better treatments that address the root causes of diseases. Genizon is conducting gene discovery programs in more than 20 common diseases.

Contacts:

Genizon BioSciences, Inc.

Henry J. Bretecher
Chief Financial Officer
+1 514 270 3991 ext. 230
henry.bretecher@genizon.com

Schwartz Communications

Lauren Arnold/Wendy Mejia
+1 781 684 0770
genizon@schwartz-pr.com